Skip to main content
. 2022 Dec 6;9:1061471. doi: 10.3389/fcvm.2022.1061471

Figure 2.

Figure 2

Kaplan-Meyer analysis of ACEi/ARB as predictor of 1-year VT recurrence in women. P < 0.05 considered significant. ACEi/ARB: angiotensin convertase enzyme inhibitor or angiotensin receptor blocker therapy. Number of patients at risk at each 50- day timepoint are reported above x-axis for the individual patient groups.